Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Increase of Options from 10% to 14% of outstanding Shares

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon Apr 06, 2023 5:19pm

102 Views

Post# 35383960

RE:RE:Increase of Options from 10% to 14% of outstanding Shares

These dreaming pumpers have mislead folks for years... especially canuckfan and unnoteable. I pity their blind followers. If you go back and read the posts over the last 3 years you will see they were leading the lambs to slaughter with 5 to 10 billion buyout claims. Have not heard a peep about buyout opportunities lately.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market